KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) Gross Margin (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 10 years of Gross Margin data on record, last reported at 90.77% in Q4 2025.

  • For Q4 2025, Gross Margin fell 84.0% year-over-year to 90.77%; the TTM value through Dec 2025 reached 91.69%, up 24.0%, while the annual FY2025 figure was 91.69%, 24.0% up from the prior year.
  • Gross Margin reached 90.77% in Q4 2025 per ACAD's latest filing, down from 92.23% in the prior quarter.
  • Across five years, Gross Margin topped out at 98.59% in Q1 2023 and bottomed at 88.85% in Q1 2024.
  • Average Gross Margin over 5 years is 94.42%, with a median of 92.78% recorded in 2023.
  • Peak YoY movement for Gross Margin: soared 645bps in 2022, then plummeted -974bps in 2024.
  • A 5-year view of Gross Margin shows it stood at 91.78% in 2021, then grew by 7bps to 98.23% in 2022, then dropped by -6bps to 92.26% in 2023, then decreased by -1bps to 91.6% in 2024, then fell by -1bps to 90.77% in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Margin were 90.77% in Q4 2025, 92.23% in Q3 2025, and 92.16% in Q2 2025.